Obesity-associated cardiovascular risk in women: hypertension and heart failure

2021 ◽  
Vol 135 (12) ◽  
pp. 1523-1544
Author(s):  
Jessica L. Faulkner

Abstract The pathogenesis of obesity-associated cardiovascular diseases begins long prior to the presentation of a cardiovascular event. In both men and women, cardiovascular events, and their associated hospitalizations and mortality, are often clinically predisposed by the presentation of a chronic cardiovascular risk factor. Obesity increases the risk of cardiovascular diseases in both sexes, however, the clinical prevalence of obesity, as well as its contribution to crucial cardiovascular risk factors is dependent on sex. The mechanisms via which obesity leads to cardiovascular risk is also discrepant in women between their premenopausal, pregnancy and postmenopausal phases of life. Emerging data indicate that at all reproductive statuses and ages, the presentation of a cardiovascular event in obese women is strongly associated with hypertension and its subsequent chronic risk factor, heart failure with preserved ejection fraction (HFpEF). In addition, emerging evidence indicates that obesity increases the risk of both hypertension and heart failure in pregnancy. This review will summarize clinical and experimental data on the female-specific prevalence and mechanisms of hypertension and heart failure in women across reproductive stages and highlight the particular risks in pregnancy as well as emerging data in a high-risk ethnicity in women of African ancestry (AA).

Author(s):  
E. Baranova ◽  
O. Bolshakova

Arterial hypertension in pregnancy is now believed to be a risk factor for future maternal cardiovascular diseases. Despite the low immediate cardiovascular risk in a population of young women, a pregnancy complicated with hypertension carries a significant additional risk of future disease.


2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
C Morbach ◽  
G Gelbrich ◽  
T Tiffe ◽  
F Eichner ◽  
M Breunig ◽  
...  

Abstract Background and aim Prevention of heart failure (HF) relies on early identification and elimination of cardiovascular risk factors. ACC/AHA guidelines define consecutive asymptomatic precursor stages of HF, i.e. stage A (with risk factors for HF), and stage B (asymptomatic cardiac dysfunction). We aimed to identify frequency and characteristics of individuals at risk for HF, i.e. stage A and B, in the general population. Methods The prospective Characteristics and Course of Heart Failure Stages A-B and Determinants of Progression (STAAB) cohort study phenotyped a representative sample of 5000 residents (aged 30–79 y) of a medium sized German town, reporting no previous HF diagnosis. Echocardiography was highly quality-controlled. We applied these definitions: HF stage A: ≥1 risk factor for HF (hypertension, arteriosclerotic disease, diabetes mellitus, obesity, metabolic syndrome), but no structural heart disease (SHD); HF stage B: asymptomatic but SHD [reduced left ventricular (LV) ejection fraction, LV hypertrophy, LV dilation, stenosis or grade 2/3 regurgitation of aortic/mitral valve, grade 2/3 diastolic dysfunction], or prior myocardial infarction; Normal (N): no risk factor and no SHD. We focused on subjects in stage B without apparent cardiovascular risk factors qualifying for A (B-not-A) compared to those with risk factors (BA) and N. The first half of the sample (n=2473) served as derivation set (D), the second half (n=2434) as validation set (V). Results We found 42% (D)/45% (V) of subjects in stage A, and 18% (D)/17% (V) in stage B. Among stage B subjects, 31% (D)/29% (V) were B-not-A. Compared to BA, B-not-A subjects were younger [47 vs. 63 y (D)/50 vs 63 years (V); both p<0.001] and more often female [78% vs 56% (D)/79% vs 62% (V); both p<0.001], had higher LV ejection fraction [59% vs 56% (D)/53% vs 48% (V); both p<0.05], lower E/e' [6.7 vs 9.9 (D)/6.9 vs. 9.3 (V); both p<0.001], higher LV volume [64 vs 59 mL/m2 (D)/54 vs 48 mL/m2 (V); both p≤0.01], lower hemoglobin [13.3 vs 13.9 g/dL (D, p=0.02)/13.4 vs 13.8 g/dL (V, p=0.08); both adjusted for sex], and lower QTc interval [423 vs 433 ms (D)/427 vs 438 ms (V); both p≤0.001). Compared to N, subjects in B-not-A were more often female [78% vs 56% (D)/79% vs 61% (V); both p<0.001], had larger QTc interval [423 vs 418 ms (D)/427 vs 420 ms (V); both p<0.05], and more often anemia [11% vs 5% (D, p=0.02)/9% vs 5% (V, p=0.12)]. Conclusions We confirmed, by extensive internal validation, the presence of a hitherto undescribed group of individuals with relevant myocardial alterations, but lacking respective risk factors. Since algorithms in primary prevention do not include echocardiography, this subgroup might be missed. Further investigations should 1) externally validate our finding, 2) study the prognostic course of subjects in group B-not-A, and 3) elaborate the material differences between B-not-A and N to identify potential further novel risk factors for HF. Acknowledgement/Funding German Ministry of Research and Education within the Comprehensive Heart Failure Centre Würzburg (BMBF 01EO1004 and 01EO1504)


Author(s):  
Marina Rieder ◽  
Nadine Gauchel ◽  
Christoph Bode ◽  
Daniel Duerschmied

Abstract Cardiovascular diseases and depression are significant health burdens and increasing evidence suggests a causal relationship between them. The incidence of depression among patients suffering from cardiovascular disease is markedly elevated, and depression itself is an established cardiovascular risk factor. Serotonin 5-hydroxytryptamin (5-HT), a biogenic amine acting as a neurotransmitter and a peripheral hormone, is involved in the pathogenesis of both, cardiovascular disease and depression. Novel cardiovascular functions of 5-HT have recently been described and will be summarized in this review. 5-HT has a broad spectrum of functions in the cardiovascular system, yet the clinical or experimental data are partly conflicting. There is further research needed to characterize the clinical effects of 5-HT in particular tissues to enable targeted pharmacological therapies.


Author(s):  
Lucas Z. Randimbinirina ◽  
Fanomezantsoa H. Randrianandrianina ◽  
Tsirimalala Rajaobelison ◽  
Jean Claude A. Rakotoarisoa ◽  
Agnes M. L. Ravalisoa

Background: Cardiovascular disease (CVD) is the primary cause of morbidity and premature mortality in chronic kidney disease (CKD). The aim of this study was to assess the frequency of cardiovascular disease and cardiovascular risk in haemodialysis population for chronic kidney disease.Methods: This was a retrospective and descriptive study for a period of 4 years from January 2016 to December 2019, performed at hemodialysis unit in Soavinandriana Hospital Center Antananarivo, including all patients, following regular hemodialysis for chronic renal failure. Demographic data, cardiovascular disease, cardiovascular risk factors, aetiology of nephropathy, haemoglobin <11 g/dl, phosphocalcic metabolism disorders and uricemia were analyzed.Results: Seventy-six patients were recorded, including 46 males (60.52%) and were women (39.47%). The average age was 59.98 years old. The risk factors of cardiovascular disease were smoking (22.36%), diabetes mellitus (46.05%), high blood pressure (71.05%), dyslipidemia (47.36%) and obesity (11.84%). Fifty-eight patients (76.31%) had a high cardiovascular risk factor. Seventy patients (22.36%) had had a history of cardiovascular diseases. Fifty-nine patients had a haemoglobin concentration under 11 g/dl (77.63%). There were 23 cases of hypocalcemia (30.26%), 22 cases of hyperphosphatemia (28.94%) and 37 cases of hyperuricemia (48.68%).Conclusions: There was a high cardiovascular risk factor in this study population. Early detection of cardiovascular diseases should be done in patients who have a high-risk factor of cardiovascular disease to decrease the mortality rate in chronic kidney diseases population. The appropriate management of modifiable risk factors is important to improve the survival of this study patients.


Author(s):  
Mazou Temgoua ◽  
Sylvain Chanseaume ◽  
hilic Enver ◽  
Kane Karamoko ◽  
Joel Tochie ◽  
...  

Cardiac arrythmia is a major complication of COVID-19. This occurs often in patients with severe COVID-19 with pre-existing cardiovascular diseases. We report an unusual case of paroxysmal atrial fibrillation in an adult male with low cardiovascular risk factor who presented with a moderate form of COVID-19.


2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
A Madika ◽  
P Nasserdine ◽  
S Langlet ◽  
B Letombe ◽  
P Devos ◽  
...  

Abstract Introduction In women, cardiovascular diseases are the leading cause of death worldwide. Prevention and diagnosis typically occur at late stages and less frequently than is men and treatments are not optimal in women. Preventive measures must be implemented, and management approaches improved. To this end, an innovative coordinated healthcare pathway was initiated at the our University Hospital for women at risk of cardiovascular diseases. Purpose The objective of this study was to describe the design of the healthcare pathway and to assess its relevance to improve prevention, diagnosis and treatment in women at cardiovascular risk. Methods The healthcare pathway “Heart, arteries and women” implemented at our University Hospital since January 1st, 2013 is based on collaboration between gynecologists and cardiologists. Women after an adverse pregnancy outcome and women at menopause with increased cardiovascular risk were referred by the gynecologist to the cardiologist for complete cardiovascular evaluation if eligible (Figure 1). Screening for both traditional and nontraditional cardiovascular risk factor and cardiovascular diseases if indicated, lifestyle counseling and adjustment of medical treatment were performed for each woman. The present study focused on post-menopausal women at risk or high cardiovascular risk according to American Heart Association (AHA) classification who had a complete cardiovascular evaluation through the healthcare pathway between January 1st, 2013 and December 31st, 2017. Results We included 690 post-menopausal women with a mean age of 58±8 years. According to AHA classification, 339 women (50,8%) were at high risk and 351 (49,2%) at risk. Cardiovascular risk control was poor with 146 current smokers (21,2%) and 264 obese women (38,3%). Only 320 women (46,4%) reached the targeted blood pressure of <140/90 mmHg and 169 (24.5%) attained their low-density lipoprotein (LDL)-cholesterol target. Among the 212 women treated for diabetes, 45,3% achieved the glycated haemoglobin (HbA1c) target of <7.0%. Lower extremity artery disease was newly diagnosed in 46 women, renal artery disease in 51 women and ischemic heart disease in 62 women. Statins, renin-angiotensin system inhibitors and antiplatelet agents were significantly more prescribed according to guidelines after the cardiovascular evaluation (p<0.001). Conclusion Our coordinated healthcare pathway based on partnership between gynecologists and cardiologists allowed to improve assessment of specific cardiovascular risk, screening, prevention and treatment of cardiovascular diseases in women. Enhanced collaboration between gynecologists and cardiologists offers a real opportunity to improve cardiovascular heath in women.


2006 ◽  
Vol 111 (1) ◽  
pp. 81-86 ◽  
Author(s):  
Brigitte Leeners ◽  
Werner Rath ◽  
Sabine Kuse ◽  
Claudia Irawan ◽  
Bruno Imthurn ◽  
...  

HDP (hypertensive diseases in pregnancy) are one of the leading causes of maternal and fetal mortality and morbidity. BMI (body mass index) is an established risk factor for pre-eclampsia, but its role in HELLP syndrome is unknown. We therefore investigated BMI as a risk factor in the development of HELLP syndrome. At the beginning of pregnancy, BMI was measured in 1067 women with a history of HDP and 1063 controls. Diagnoses of HDP were classified according to ISSHP (International Society for the Study of Hypertension in Pregnancy) and BMI according to WHO (World Health Organization) criteria. After verification of exclusion criteria and matching for confounders, 687 women with hypertensive diseases in pregnancy and 601 controls remained for statistical evaluation by χ2 test and multiple logistic regressions. As a continuous variable, the increase in BMI was associated with an increase in the development of gestational hypertension {OR (odds ratio), 1.1 [95% CI (confidence interval) 1.062–1.197]} and pre-eclampsia [OR, 1.1 (95% CI, 1.055–1.144)]}, but not for HELLP syndrome. According to WHO definitions, overweight women (BMI ≥25 and <30 kg/m2) had a 2-fold (95% CI, 1.365–2.983) risk and obese women (BMI ≥30 kg/m2) had a 3.2-fold (95% CI, 1.7–5.909) risk of developing pre-eclampsia when compared with women of normal weight (BMI ≥15.5 and <25 kg/m2). Being overweight or having obesity had no effect on the risk of HELLP syndrome. As an increased BMI is correlated with the risk of developing pre-eclampsia but not HELLP syndrome, both diseases have a different risk profile. This finding supports that underlying physiological mechanisms in pre-eclampsia vary from those in HELLP syndrome.


Sign in / Sign up

Export Citation Format

Share Document